Inactive Instrument

Luckwel Pharmaceuticals Inc.

LWEL

US54959L1017

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020

June 11, 2021 at 02:51 am IST

Luckwel Pharmaceuticals Inc. announced earnings results for the full year ended March 31, 2020. For the full year, the company announced net loss was USD 536,432 compared to USD 622,526 a year ago. Basic loss per share from continuing operations was USD 0.004 compared to USD 0.005 a year ago.

Latest news about Luckwel Pharmaceuticals Inc.

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	07/21/07	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	11/21/11	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited	14/21/14	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding	20/21/20	CI
Luckwel Pharmaceuticals Inc. Announces Address Changes	04/21/04	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	14/20/14	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	15/19/15	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	02/19/02	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	14/19/14	CI
Luckycom Pharmaceuticals Inc. has Changed its Name to Luckwel Pharmaceuticals Inc	13/18/13	CI
Luckwel Pharmaceuticals Inc. has Changed its Ticker to LWEL from LCOM	13/18/13	CI
Luckycom, Inc. will Change its Name to Luckycom Pharmaceuticals Inc	18/17/18	CI
Luckycom Pharmaceuticals Inc. will Change its Ticker to LCOM from LKYM	18/17/18	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	02/16/02	CI
Luckycom Inc Announces Fiscal Year Change from February 28 or 29 to March 31	12/16/12	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	01/15/01	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	15/14/15	CI

Chart Luckwel Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
SCREAMING EAGLE ACQUISITION CORP.	-4.43%	104.44Cr
OKLO INC.	-8.65%	103.17Cr
CHURCHILL CAPITAL CORP VII	+2.19%	98Cr
APPLE ISPORTS GROUP, INC.	+41.91%	87Cr
PERELLA WEINBERG PARTNERS	+22.61%	81Cr
E7 GROUP	+8.62%	67Cr
ARES ACQUISITION CORPORATION II	+1.73%	66Cr
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	60Cr
ADMIRAL ACQUISITION LIMITED	+3.61%	50Cr

Shell Companies